{"title":"痴呆风险评分预测轻度认知障碍的评估:cogrisk、CAIDE、LIBRA和ANU-ADRI的比较","authors":"Md Hamidul Huque, Kaarin J Anstey","doi":"10.1016/j.tjpad.2025.100324","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Given the lack of widely accessible dementia treatments, identifying individuals at high risk of dementia is vital for prevention. No prior study has compared multiple validated dementia risk tools for predicting mild cognitive impairment (MCI) across multiple datasets. We assess the performance of the CogDrisk, ANU-ADRI, CAIDE, and LIBRA in predicting MCI.</p><p><strong>Method: </strong>Data were obtained from the ARIC, Whitehall II, and PATH Through Life cohorts. Participants without dementia or MCI at baseline were included. Risk scores were computed using available risk factors and analysed using logistic regression, with Area Under the Curve (AUC) estimates. Multiple imputation was used to evaluate the impact of missing data.</p><p><strong>Results: </strong>The ARIC (n = 5778), Whitehall II (n = 6387), and PATH (n = 2115) cohorts had mean baseline ages of 51.9, 55.8, and 62.5 years, with follow-ups of 28.2, 15.7, and 11.2 years, respectively. AUCs for MCI prediction were generally similar across tools and datasets. Dementia prevalence following MCI was highest in ARIC (23.6%), followed by Whitehall II (14.1%) and PATH (7.0%). In ARIC, CogDrisk showed slightly better AUCs for predicting MCI cases that progressed to dementia. Whitehall II and PATH showed mixed results, with wider confidence intervals for progressing MCI cases, and higher AUCs for non-progressing MCI cases using CogDrisk and ANU-ADRI. All tools performed consistently when predicting dementia without prior MCI.</p><p><strong>Discussion: </strong>Dementia risk scores demonstrated comparable performance of MCI prediction and are more sensitive for identifying cases that progress to dementia, supporting their greater utility for informing risk reduction strategies.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":" ","pages":"100324"},"PeriodicalIF":7.8000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501335/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessment of dementia risk scores in predicting mild cognitive impairment: A comparison of CogDrisk, CAIDE, LIBRA, and ANU-ADRI.\",\"authors\":\"Md Hamidul Huque, Kaarin J Anstey\",\"doi\":\"10.1016/j.tjpad.2025.100324\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Given the lack of widely accessible dementia treatments, identifying individuals at high risk of dementia is vital for prevention. No prior study has compared multiple validated dementia risk tools for predicting mild cognitive impairment (MCI) across multiple datasets. We assess the performance of the CogDrisk, ANU-ADRI, CAIDE, and LIBRA in predicting MCI.</p><p><strong>Method: </strong>Data were obtained from the ARIC, Whitehall II, and PATH Through Life cohorts. Participants without dementia or MCI at baseline were included. Risk scores were computed using available risk factors and analysed using logistic regression, with Area Under the Curve (AUC) estimates. Multiple imputation was used to evaluate the impact of missing data.</p><p><strong>Results: </strong>The ARIC (n = 5778), Whitehall II (n = 6387), and PATH (n = 2115) cohorts had mean baseline ages of 51.9, 55.8, and 62.5 years, with follow-ups of 28.2, 15.7, and 11.2 years, respectively. AUCs for MCI prediction were generally similar across tools and datasets. Dementia prevalence following MCI was highest in ARIC (23.6%), followed by Whitehall II (14.1%) and PATH (7.0%). In ARIC, CogDrisk showed slightly better AUCs for predicting MCI cases that progressed to dementia. Whitehall II and PATH showed mixed results, with wider confidence intervals for progressing MCI cases, and higher AUCs for non-progressing MCI cases using CogDrisk and ANU-ADRI. All tools performed consistently when predicting dementia without prior MCI.</p><p><strong>Discussion: </strong>Dementia risk scores demonstrated comparable performance of MCI prediction and are more sensitive for identifying cases that progress to dementia, supporting their greater utility for informing risk reduction strategies.</p>\",\"PeriodicalId\":22711,\"journal\":{\"name\":\"The Journal of Prevention of Alzheimer's Disease\",\"volume\":\" \",\"pages\":\"100324\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501335/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Prevention of Alzheimer's Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tjpad.2025.100324\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BUSINESS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tjpad.2025.100324","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}
引用次数: 0
摘要
背景:鉴于缺乏广泛可及的痴呆症治疗方法,识别痴呆症高危人群对于预防至关重要。之前没有研究比较多个数据集中预测轻度认知障碍(MCI)的多个验证痴呆风险工具。我们评估了cogrisk、ANU-ADRI、CAIDE和LIBRA在预测MCI方面的表现。方法:数据来自ARIC、Whitehall II和PATH Through Life队列。基线时无痴呆或轻度认知障碍的参与者被纳入研究。使用可用的风险因素计算风险评分,并使用逻辑回归和曲线下面积(AUC)估计进行分析。采用多重插值法评估缺失数据的影响。结果:ARIC (n = 5778)、Whitehall II (n = 6387)和PATH (n = 2115)队列的平均基线年龄分别为51.9岁、55.8岁和62.5岁,随访时间分别为28.2年、15.7年和11.2年。MCI预测的auc在不同的工具和数据集上大致相似。MCI后痴呆患病率最高的是ARIC(23.6%),其次是Whitehall II(14.1%)和PATH(7.0%)。在ARIC中,cogrisk在预测MCI病例进展为痴呆方面显示出稍好的auc。Whitehall II和PATH显示出混合结果,使用cogrisk和ANU-ADRI,进展性MCI病例的置信区间更宽,非进展性MCI病例的auc更高。所有工具在预测无MCI的痴呆时表现一致。讨论:痴呆风险评分在MCI预测方面具有可比性,并且在识别进展为痴呆的病例方面更为敏感,这支持了它们在告知降低风险策略方面的更大效用。
Assessment of dementia risk scores in predicting mild cognitive impairment: A comparison of CogDrisk, CAIDE, LIBRA, and ANU-ADRI.
Background: Given the lack of widely accessible dementia treatments, identifying individuals at high risk of dementia is vital for prevention. No prior study has compared multiple validated dementia risk tools for predicting mild cognitive impairment (MCI) across multiple datasets. We assess the performance of the CogDrisk, ANU-ADRI, CAIDE, and LIBRA in predicting MCI.
Method: Data were obtained from the ARIC, Whitehall II, and PATH Through Life cohorts. Participants without dementia or MCI at baseline were included. Risk scores were computed using available risk factors and analysed using logistic regression, with Area Under the Curve (AUC) estimates. Multiple imputation was used to evaluate the impact of missing data.
Results: The ARIC (n = 5778), Whitehall II (n = 6387), and PATH (n = 2115) cohorts had mean baseline ages of 51.9, 55.8, and 62.5 years, with follow-ups of 28.2, 15.7, and 11.2 years, respectively. AUCs for MCI prediction were generally similar across tools and datasets. Dementia prevalence following MCI was highest in ARIC (23.6%), followed by Whitehall II (14.1%) and PATH (7.0%). In ARIC, CogDrisk showed slightly better AUCs for predicting MCI cases that progressed to dementia. Whitehall II and PATH showed mixed results, with wider confidence intervals for progressing MCI cases, and higher AUCs for non-progressing MCI cases using CogDrisk and ANU-ADRI. All tools performed consistently when predicting dementia without prior MCI.
Discussion: Dementia risk scores demonstrated comparable performance of MCI prediction and are more sensitive for identifying cases that progress to dementia, supporting their greater utility for informing risk reduction strategies.
期刊介绍:
The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.